Business context and reporting period
Adicet Bio, Inc. filed this unaudited Form 10-Q for the quarter and nine months ended September 30, 2022. It is a clinical-stage biotechnology company developing allogeneic gamma delta T-cell therapies; it has no approved products and has not generated product-sales revenue. Its lead candidate, ADI-001, is in a Phase 1 study for relapsed or refractory B-cell non-Hodgkin lymphoma (NHL).
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue, related party | $0 | $3.4 million | $25.0 million | $4.3 million |
| Research and development expense | $16.6 million | $11.9 million | $46.2 million | $34.3 million |
| General and administrative expense | $6.4 million | $5.2 million | $19.7 million | $15.9 million |
| Operating loss | $23.0 million | $13.7 million | $41.0 million | $45.9 million |
| Net loss | $22.0 million | $14.0 million | $39.9 million | $46.2 million |
| Net loss per share, basic and diluted | $0.53 | $0.44 | $0.98 | $1.54 |
Cash and liquidity: Cash and cash equivalents were $282.7 million at September 30, 2022, versus $277.5 million at December 31, 2021. Nine-month operating cash use was $25.9 million; capital spending was $10.3 million, primarily for Redwood City facilities; financing provided $41.2 million, including $43.4 million net proceeds from the August ATM stock sale. Management said cash was expected to fund forecasted operating expenses, capital expenditures and debt service for at least 12 months after the financial statements’ issuance. Separately, the risk factors state the company believed it was capitalized into the first half of 2025; both are management estimates, not guarantees.
Balance sheet and debt: Total assets were $354.3 million, total liabilities $36.6 million and stockholders’ equity $317.7 million. The company reported no term-loan borrowings and said it was in compliance with loan covenants. It had $4.4 million of outstanding non-formula ancillary services and $10.6 million of term-loan availability under the PacWest facility. Operating lease liabilities totaled $21.7 million. The filing does not present a meaningful product gross margin; revenue was collaboration-related, not product sales.
Material changes versus the prior comparable period
- Q3 revenue fell to zero because Regeneron collaboration performance obligations had been completed in Q1 2022. Nine-month revenue rose to $25.0 million, primarily from Regeneron’s $20.0 million January option exercise for ADI-002, plus $5.0 million recognized under the collaboration.
- Q3 operating expenses increased 34%, with R&D up 39% and G&A up 23%, primarily reflecting higher headcount and personnel costs. Q3 net loss widened year over year as revenue ceased and expenses rose.
- Nine-month net loss narrowed year over year, mainly because of the ADI-002 option revenue and higher interest income, despite increased operating expenses.
- In August, the company sold 2.6 million shares at $17.23 per share for $43.4 million net proceeds. It disclosed plans for a prospectus supplement covering up to $100 million of ATM sales, including unsold capacity and an additional $70 million.
- Construction spending increased property and equipment; the company moved operations to its Redwood City facility in June and expanded leased space by 12,204 square feet.
Outlook, commentary, risks and unusual items
- Management expects substantial operating losses and negative operating cash flows to continue, with no significant product revenue expected until a candidate is approved and commercialized, if ever. It anticipates needing substantial additional capital.
- ADI-001 received FDA Fast Track designation in April 2022. The company reported positive interim Phase 1 data in June and said updated data using a July 15, 2022 cutoff were scheduled for presentation at the December 2022 ASH meeting. Interim results may change as data mature.
- ADI-002 rights were licensed exclusively worldwide to Regeneron after its option exercise. Adicet declined to co-fund development and is entitled to high-single-digit royalties on potential net sales, subject to the agreement.
- The company planned to begin manufacturing operations at its Redwood City facility in Q4 2022. It continued to rely on third-party suppliers and manufacturers, creating supply, quality, timing and cost risks.
- Key risks include clinical safety or efficacy failure, trial delays or enrollment challenges, regulatory uncertainty, manufacturing scale-up, dependence on Regeneron and other third parties, additional financing needs and potential dilution. COVID-19, inflation, higher interest rates, supply-chain constraints and the Russia-Ukraine conflict were also cited as risks.
- No legal proceedings were reported that management expected to have a material adverse effect. Management concluded disclosure controls were effective as of September 30, 2022; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether updated ADI-001 clinical data, including safety, efficacy, durability and patient numbers, support the positive interim findings.
- Actual cash burn, expected runway and future financing needs; reconcile the stated minimum 12-month funding expectation with the separate first-half-2025 capitalization estimate.
- Progress, timing and costs for Redwood City manufacturing operations, and whether internal capacity reduces reliance on third parties.
- Whether the planned ATM prospectus was filed and how much additional stock is ultimately sold, including resulting dilution.
- Any changes to Regeneron collaboration economics, remaining options, royalty prospects or the timing of potential payments.